Saga Diagnostics is a biotechnology company developing advanced diagnostic methods to detect and monitor cancer after treatment. The company’s technology is based on the analysis of tumour-specific structural variations in DNA from blood samples, in contrast to more traditional methods that focus on individual mutations. This enables highly sensitive detection of residual disease and thereby earlier identification of cancer recurrence, which can be critical for treatment outcomes.

Sciety and its investor network participated in a financing round in Saga Diagnostics in 2021 together with Segulah Medical Acceleration, which was the largest investor in the round. In total, Saga Diagnostics raised SEK 106 million in the round, which was led by Sciety. The capital enabled accelerated development with a focus on the lead product Pathlight™. Since the financing, the company has achieved several key milestones, including clinical validation of Pathlight™ with strong results, commercial launch in the U.S., and Pathlight™ obtaining Medicare reimbursement for breast cancer, which is a key prerequisite for commercial scaling in the U.S. market.

The acquisition of Saga Diagnostics takes place at a time when global interest in precision diagnostics is increasing, driven by the need for more personalised cancer treatment and the opportunity for earlier intervention. Particularly strong growth is seen in liquid biopsy-based solutions, which enable the detection of minimal residual disease (MRD) and thereby earlier detection of cancer recurrence.

“When Sciety invested in Saga Diagnostics in 2021, we saw clear potential in the company’s technology to improve how cancer is detected and monitored. Since then, the company has established a strong position with clear clinical and commercial relevance in a rapidly growing field. This transaction creates the conditions for the technology to reach more patients faster. The acquisition also marks Sciety’s tenth exit and represents an important milestone for us and our co-investors,” says Andreas Lindblom, Managing Partner at Sciety.

The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in the third quarter of 2026. Following closing, Saga Diagnostics’ platform will be integrated into Foundation Medicine.

For more information, please contact:
Andreas Lindblom, Managing Partner, Sciety
andreas.lindblom@sciety.se | +46 70 375 73 73

About Saga Diagnostics
Saga Diagnostics is a biotechnology company developing diagnostic tests to identify minimal residual disease (MRD) and thereby support treatment decisions in oncology. The company’s lead product, Pathlight™, is a highly sensitive blood-based test used to detect residual cancer at an early stage. The test is commercially available in the U.S. and reimbursed for patients with early-stage breast cancer. The company collaborates with pharmaceutical and biotechnology companies as well as other commercial partners across the development continuum, from early research to late-stage clinical development. Headquarters and laboratory operations are based in Research Triangle Park, North Carolina, USA. For more information, visit sagadiagnostics.com.

About Sciety
Sciety is a long-term investment partner and investor in life science and health tech, with a focus on the Nordic region. We identify and invest in growth companies with the potential to create significant value for both investors and society, and with a clear path towards a future exit. We lead investment processes and invest alongside leading venture capital firms, family offices, and through our investor network, Sciety Venture Partners. Our goal is for growth companies within life science and digital health to scale and succeed, making scientific breakthroughs in medicine and technology accessible to people all over the world. For more information, visit sciety.com and follow us on LinkedIn.